CT-INDUSTRIAL-FLOW
Leading industrial pumping solutions provider Industrial Flow Solutions ™, headquartered in New Haven, Conn., USA, announced today the agreement to acquire Clearwater Controls Ltd. ™, based in Glasgow, Scotland. Clearwater Controls offers a broad line of wastewater solutions, beginning with its leading deragging intelligent systems to solve specific pumping problems, to more advanced monitoring technology to optimize and manage entire water networks. Terms of the acquisition were not disclosed. Clearwater Controls will retain its company name and brand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005200/en/
Clearwater Controls is known worldwide for the DERAGGER ™+ line of intelligent deragging control systems. The company is bringing the Internet of Things (IoT) to industry sectors with its newest innovation: cloud-based data analytics and management for improved monitoring of water networks.
Clearwater Controls’ solutions allow engineers and operators to analyze and create baseline data on the performance of their pump networks in real time to optimize operations, identify problems, perform money-saving predictive maintenance, and avoid potentially harmful and costly environmental impacts. These smart interventions will transform the industry from its historic reactive approach to a predictive asset management model.
Incorporating Clearwater Controls’ DERAGGER PRO pump station controller across its brands will bring intelligent efficiency to nearly all product lines of Industrial Flow Solutions, particularly the innovative OverWatch™ Direct In-Line Pumping System platform. Clearwater Controls’ complementary products and technology will provide greater value to customers seeking to reduce startup time, strengthen reliability and provide real-time cloud-based data.
“As technology and smart data bring new changes to the water industry, this acquisition will establish Industrial Flow Solutions and Clearwater Controls as leaders in the new digital revolution,” said John Wilson, President of Industrial Flow Solutions. “This new partnership supports our combined missions to transform any industry that relies on high usage of water and the need for treatment,“ he added.
Wilson expects a dramatic increase in Clearwater Controls’ business as it develops a greater product range for the DERAGGER+ and expands its global customer base.
“This acquisition is of mutual benefit to both companies, making each uniquely more competitive. We have common values of being customer focused, highly responsive, innovative, collaborative, supportive, and ambitious,” Wilson said. “We will provide Clearwater Controls with resources and expertise to strengthen its business overall. Reciprocally, Clearwater Controls’ unique and agnostic control solutions open a huge opportunity for Industrial Flow Solutions to access a worldwide market,” Wilson added.
“Clearwater Controls is taking the lead in seizing the groundswell of interest and momentum around intelligent monitoring and management of wastewater networks,” said Simon Crompton, Managing Director, Clearwater Controls. “Our partnership with Industrial Flow Solutions provides us with a greater footprint to advance pumping technology worldwide,” said Crompton.
About Industrial Flow Solutions
Industrial Flow Solutions specializes in the design, manufacturing, sales and service of pumping and fluid management solutions for harsh, rugged environments. With OverWatch™ direct in-line pump systems, BJM Pumps® products and Stancor® Pumps and Controls, the company offers a comprehensive portfolio of submersible and direct in-line pumps and controls ideal for industrial, commercial and municipal wastewater applications. Industrial Flow Solutions, headquartered in New Haven, Conn., is a portfolio company of May River Capital , a Chicago-based private-equity firm focused on lower middle-market industrial growth companies. For more information, please visit https://flowsolutions.com .
About Clearwater Controls Ltd.
Clearwater Controls launched in 2009 as the research and development division of ID Systems. The company has conceived, developed, and delivered a suite of intelligent pump monitoring and anti-ragging solutions, built around its unique and patented technology. Based in Glasgow, Scotland, United Kingdom, with a rapidly expanding operation in the United States, Clearwater Controls delivers solutions to clients across the UK, Ireland, Continental Europe, and North America. For more information, please visit https://clearwatercontrols.co.uk .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005200/en/
Link:
Social Media:
https://www.facebook.com/Industrial-Flow-Solutions-102601071895549
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom